These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23422317)

  • 1. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer.
    Howard-McNatt M; Lawrence J; Melin SA; Levine EA; Shen P; Stewart JH
    Am J Surg; 2013 Apr; 205(4):397-401. PubMed ID: 23422317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer.
    Pastoriza JM; Karagiannis GS; Lin J; Lanjewar S; Entenberg D; Condeelis JS; Sparano JA; Xue X; Rohan TE; Oktay MH
    Clin Exp Metastasis; 2018 Oct; 35(7):613-623. PubMed ID: 30136072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
    Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
    J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does race predict survival for women with invasive breast cancer?
    Walsh SM; Zabor EC; Stempel M; Morrow M; Gemignani ML
    Cancer; 2019 Sep; 125(18):3139-3146. PubMed ID: 31206623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate.
    Sweeting RS; Klauber-Demore N; Meyers MO; Deal AM; Burrows EM; Drobish AA; Anders CK; Carey LA
    Am Surg; 2011 Jul; 77(7):850-5. PubMed ID: 21944346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
    Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
    J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacophore-based classification better predicts the outcomes of HER2-negative breast cancer patients receiving the anthracycline- and/or taxane-based neoadjuvant chemotherapy.
    Li X; Sun H; Liu Q; Liu Y; Hou Y; Jin W
    Cancer Med; 2021 Jul; 10(13):4658-4674. PubMed ID: 34076352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
    Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
    Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
    Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
    Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
    Yang H; Zhou L; Wang S; Cao Y; Tong F; Liu P; Zhou B; Cheng L; Liu M; Liu H; Xie F; Guo J; Wang S; Peng Y
    Medicine (Baltimore); 2018 Oct; 97(40):e12690. PubMed ID: 30290661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER
    Hayashi N; Yagata H; Tsugawa K; Kajiura Y; Yoshida A; Takei J; Yamauchi H; Nakamura S
    Clin Breast Cancer; 2020 Dec; 20(6):462-468. PubMed ID: 33046356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico.
    Villarreal-Garza C; Soto-Perez-de-Celis E; Sifuentes E; Ruano S; Baez-Revueltas B; Lara-Medina F; Arce-Salinas C; Alvarado-Miranda A; Chavarri-Guerra Y; Caro-Sanchez C; Castañeda-Soto N; Bargallo-Rocha E; Mohar A
    Breast; 2015 Jun; 24(3):218-23. PubMed ID: 25698148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial disparities in treatment and survival among women with early-stage breast cancer.
    Hershman D; McBride R; Jacobson JS; Lamerato L; Roberts K; Grann VR; Neugut AI
    J Clin Oncol; 2005 Sep; 23(27):6639-46. PubMed ID: 16170171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are There Differences in Treatment and Survival Between Poor, Older Black and White Women with Breast Cancer?
    Aggarwal H; Callahan CM; Miller KD; Tu W; Loehrer PJ
    J Am Geriatr Soc; 2015 Oct; 63(10):2008-13. PubMed ID: 26456765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy.
    Wright JL; Reis IM; Zhao W; Panoff JE; Takita C; Sujoy V; Gomez CR; Jorda M; Franceschi D; Hurley J
    Breast; 2012 Jun; 21(3):276-83. PubMed ID: 22178596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.